A phase II trial of tisagenlecleucel in first-line high-risk (HR) pediatric and young adult patients with B-cell acute lymphoblastic leukemia (B-ALL) who are minimal residual disease (MRD) positive at the end of consolidation (EOC) therapy
Phase of Trial: Phase II
Latest Information Update: 30 Nov 2019
Price : $35 *
At a glance
- Drugs Tisagenlecleucel (Primary) ; Cyclophosphamide; Cytarabine; Etoposide; Fludarabine; Tocilizumab
- Indications Precursor B-cell lymphoblastic leukaemia-lymphoma
- Focus Therapeutic Use
- Acronyms CASSIOPEIA
- Sponsors Novartis; Novartis Pharmaceuticals
- 26 Jun 2019 Planned End Date changed from 28 Jun 2027 to 26 Aug 2027.
- 26 Jun 2019 Status changed from not yet recruiting to recruiting.
- 14 May 2019 Planned initiation date changed from 30 Apr 2019 to 31 May 2019.